A team at Cambridge University has unveiled an artificial intelligence model that dramatically accelerates the process of identifying new medicines.
The system analysed over 200 million molecular compounds and identified 47 promising candidates for treating antibiotic-resistant infections.
Pharmaceutical companies have already expressed interest in licensing the technology, which could reduce development costs by billions.
Ethics experts have called for careful oversight as AI increasingly shapes medical research and patient care decisions.